Sarilumab, Drugs Monitor

(03 Feb 2021) Sarilumab- not found efficacious in COVID-19 hospitalized patients

February 5, 2021

Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial https://www.medrxiv.org/content/10.1101/2021.02.01.21250769v1 NCT04327388- Between March 28 and July 3, 2020, 420 patients were randomised; 416 received treatment (placebo, n=84; sarilumab 200 mg,… Continue reading "(03 Feb 2021) Sarilumab- not found efficacious in COVID-19 hospitalized patients"

(13 Oct 2020) Sarilumab- beneficial clinical outcome and good safety

October 17, 2020

Sarilumab use in severe SARS-CoV-2 pneumonia https://doi.org/10.1016/j.eclinm.2020.100553 Of the 53 SARS-CoV-2(pos) patients receiving Sarilumab, 39(73.6%) were treated in medical wards [66.7% with a single infusion; median PaO2/FiO2:146(IQR:120-212)] while 14(26.4%) in ICU [92.6% with a second infusion; median PaO2/FiO2: 112(IQR:100-141.5)].Within the… Continue reading "(13 Oct 2020) Sarilumab- beneficial clinical outcome and good safety"

(04 July 2020) Sarilumab- At day 28, not significant difference between sarilumab and SoC

July 7, 2020

Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study https://ard.bmj.com/content/early/2020/07/03/annrheumdis-2020-218122 In an open-label study of sarilumab in severe COVID-19 pneumonia (PaO2/FiO2 <300 mm Hg) with hyperinflammation (elevated inflammatory markers and serum IL-6 levels), sarilumab… Continue reading "(04 July 2020) Sarilumab- At day 28, not significant difference between sarilumab and SoC"

(18 May 2020) Sarilumab- promising clinical benefit and good safety

May 19, 2020

Sarilumab use in severe SARS-CoV-2 pneumonia https://doi.org/10.1101/2020.05.14.20094144 In an observational clinical cohort study, of the 53 SARS-CoV-2 patients receiving Sarilumab, 39 (73.6%) were treated in medical wards (66.7% with a single infusion) while 14 (26.4%) in ICU (92.6% with a… Continue reading "(18 May 2020) Sarilumab- promising clinical benefit and good safety"

Tag: Sarilumab

(03 Feb 2021) Sarilumab- not found efficacious in COVID-19 hospitalized patients

(13 Oct 2020) Sarilumab- beneficial clinical outcome and good safety

(04 July 2020) Sarilumab- At day 28, not significant difference between sarilumab and SoC

(18 May 2020) Sarilumab- promising clinical benefit and good safety